EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

A novel home-based, combined occipital and trigeminal afferent stimulation therapy for major depressive disorder: Efficacy and safety results from a double-blind multicenter randomized sham-controlled study

Linda L Carpenter, Mark S George, Nancy Navarro, Lisa Deutsch, Andrew F Leuchter

Brain Stimulation · 2025-09 · 18 (5) · 1695-1704

DOI: 10.1016/j.brs.2025.08.022 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Brain Stimulation, 2025-09. Verfasst von Linda L Carpenter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Butler Hospital Neuromodulation Research Facility, Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, 345 Blacks…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Electric Stimulation Therapy, Trigeminal Nerve, Occipital Lobe. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Patients with Major Depressive Disorder (MDD) who fail to achieve satisfactory benefits with existing antidepressants have limited treatment options. This study assessed the safety and efficacy of a novel non-invasive brain neuromodulation therapy which delivers external Combined Occipital and Trigeminal Afferent Stimulation (eCOT-AS) as a therapeutic option for MDD. METHODS: 124 adults with MDD who failed to respond to antidepressants and with a baseline Hamilton Depression Rating Scale (HDRS21) score ≥20 were enrolled in a randomized, double-blind, sham-controlled, multicenter study of self-administered daily active or sham eCOT-AS (n = 62 per arm) for eight weeks. The double-blind phase was followed by an 8-week active open label phase. HDRS17 was used to assess outcomes. RESULTS: Baseline depression scores were similar for both groups and reflected moderate to very severe depression. After 8 weeks of treatment, the adjusted mean HDRS17 improvement in the active treatment group was 8.62 points versus 6.01 for sham (p = 0.0196). Compared to sham treatment, participants receiving active treatment had significantly higher remission rates (21.3 % vs 6.0 %, p = 0.027) and achieved significantly more shifts to lower HDRS17 depression severity categories. Participants further improved during the subsequent eight weeks of open-label active stimulation with a mean reduction of almost 10 points from baseline and achieved a remission rate of 32 %. The treatment was well-tolerated with generally mild and transient adverse events. CONCLUSION: This home-based brain neuromodulation system is safe and effective in treating depression. These findings support eCOT-AS as a promising new adjunct therapy for MDD patients with nonresponse to antidepressants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderElectric Stimulation TherapyTrigeminal NerveOccipital LobeHumansMaleDouble-Blind MethodFemaleAdultMiddle AgedTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

External combined occipital and trigeminal afferent stimulationMajor depressive disorderNeuromodulation therapyRandomized clinical study

Autor:innen und Institutionen

  • Butler Hospital Neuromodulation Research Facility, Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, 345 Blackstone Boulevard, Providence, RI, 02903, USA. Electronic address: linda_…
  • Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC, 29425, USA; Ralph H Johnson VA Medical Center, Charleston, SC, 29425, USA.
  • San Marcus Research Clinic, 16420 NW 59th Avenue, Miami Lakes, FL, 33014, USA.
  • BioStats Statistical Consulting Ltd., 15 Nahal Sorek Street, Modiin, 7170717, Israel.
  • Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, Suite 57-456, Los…

Förderung

  • Abbott Laboratories

Zitieren

APA

Carpenter, L. L., George, M. S., Navarro, N., Deutsch, L., & Leuchter, A. F. (2025). A novel home-based, combined occipital and trigeminal afferent stimulation therapy for major depressive disorder: Efficacy and safety results from a double-blind multicenter randomized sham-controlled study. Brain Stimulation, 18(5), 1695-1704. https://doi.org/10.1016/j.brs.2025.08.022

Vancouver

Carpenter LL, George MS, Navarro N, Deutsch L, Leuchter AF. A novel home-based, combined occipital and trigeminal afferent stimulation therapy for major depressive disorder: Efficacy and safety results from a double-blind multicenter randomized sham-controlled study. Brain Stimulation. 2025;18(5):1695-1704. doi:10.1016/j.brs.2025.08.022

BibTeX
@article{Carpenter2025,
  author = {Carpenter, Linda L and George, Mark S and Navarro, Nancy and Deutsch, Lisa and Leuchter, Andrew F},
  title = {A novel home-based, combined occipital and trigeminal afferent stimulation therapy for major depressive disorder: Efficacy and safety results from a double-blind multicenter randomized sham-controlled study},
  journal = {Brain Stimulation},
  year = {2025},
  volume = {18},
  number = {5},
  pages = {1695--1704},
  doi = {10.1016/j.brs.2025.08.022}
}
Kostenlos starten →